The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation

Pertuzumab (Perjeta) is an anti-HER2 monoclonal antibody that is used for treatment of HER2-positive breast cancers in combination with trastuzumab (Herceptin) and docetaxel and showed promising clinical outcomes. Pertuzumab is suggested to block heterodimerization of HER2 with EGFR and HER3 that ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Nami, Babak, Maadi, Hamid, Wang, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468664/
https://www.ncbi.nlm.nih.gov/pubmed/30884851
http://dx.doi.org/10.3390/cancers11030375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468664/
https://www.ncbi.nlm.nih.gov/pubmed/30884851
http://dx.doi.org/10.3390/cancers11030375

Ejemplares similares